2025-04-08 17:44:22
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Gland Pharma Ltd Q2 FY2023 consolidated net profit up QoQ at Rs. 241.24 crores
Posted On : 2022-10-26 19:14:40( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 1110.028 crores during the period ended September 30, 2022 as compared to Rs. 931.289 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 241.242 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 229.169 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 14.65 for the period ended September 30, 2022 as compared to Rs. 13.92 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 1110.028 crs | ₹931.289 crs |  19.19% |
| Net Profit | ₹241.242 crs | ₹229.169 crs | 5.27% |
| EPS | ₹14.65 | ₹13.92 | 5.24% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 1110.028 crores during the period ended September 30, 2022 as compared to Rs.1131.666 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.241.242 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.302.081 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.14.65 for the period ended September 30, 2022 as compared to Rs.18.37 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 1110.028 crs | ₹1131.666 crs |  -1.91% |
| Net Profit | ₹241.242 crs | ₹302.081 crs | -20.14% |
| EPS | ₹14.65 | ₹18.37 | -20.25% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.2041.317 crores during the 6 Months period ended September 30, 2022 as compared to Rs.2347.404 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.470.411 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.652.733 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.28.57 for the 6 Months period ended September 30, 2022 as compared to Rs.39.78 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹2041.317 crs | ₹2347.404 crs | -13.04% |
| Net Profit | ₹470.411 crs | ₹652.733 crs | -27.93% |
| EPS | ₹28.57 | ₹39.78 | -28.18% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 2189.75 as compared to the previous close of Rs. 2193.20. The total number of shares traded during the day was 1182 in over 394 trades.
The stock hit an intraday high of Rs. 2210.00 and intraday low of 2180.90. The net turnover during the day was Rs. 2590157.00.
